Antibody Drug Conjugate Market: By Types (Monoclonal Antibodies, Linker), Product (Adcertis, Kadcyla) Technology (Immunogen Technology, Immunomedics Technology), Applications (Leukemia, Lymphoma) End-Users (Biotechnology Companies) - Forecast 2030
ID: MRFR/Pharma/0607-HCR | February 2021 | Region: Global | 140 Pages
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Antibody Drug Conjugate Market, by Type
6.1 Introduction
6.2 Monoclonal Antibodies
6.2.1 Market Estimates & Forecast, 2020-2027
6.3 Linker
6.3.1 Market Estimates & Forecast, 2020-2027
6.4 Drug/Toxin
6.4.1 Market Estimates & Forecast, 2020-2027
6.5 Others
Chapter 7. Global Antibody Drug Conjugate Market, by Application
7.1 Introduction
7.2 Leukemia
7.2.1 Market Estimates & Forecast, 2020-2027
7.2.2 Acute Myeloid Leukemia (AML)
7.2.2.1 Market Estimates & Forecast, 2020-2027
7.2.3 Chronic Myeloid Leukemia (CML)
7.2.3.1 Market Estimates & Forecast, 2020-2027
7.2.4 Acute Lymphocytic Leukemia (ALL)
7.2.4.1 Market Estimates & Forecast, 2020-2027
7.2.5 Chronic Lymphocytic Leukemia (CLL)
7.2.5.1 Market Estimates & Forecast, 2020-2027
7.3 Prostate Cancer
7.3.1 Market Estimates & Forecast, 2020-2027
7.4 Kidney Cancer
7.4.1 Market Estimates & Forecast, 2020-2027
7.5 Pancreas Cancer
7.5.1 Market Estimates & Forecast, 2020-2027
7.6 Ovary Cancer
7.6.1 Market Estimates & Forecast, 2020-2027
7.7 Glioblastoma
7.7.1 Market Estimates & Forecast, 2020-2027
7.8 Lung Cancer
7.8.1 Market Estimates & Forecast, 2020-2027
7.9 Colon Cancer
7.9.1 Market Estimates & Forecast, 2020-2027
7.10 Breast Cancer
7.10.1 Market Estimates & Forecast, 2020-2027
7.11 Skin Cancer
7.11.1 Market Estimates & Forecast, 2020-2027
7.12 Solid Tumors
7.12.1 Market Estimates & Forecast, 2020-2027
7.13 Multiple Myeloma
7.13.1 Market Estimates & Forecast, 2020-2027
7.14 Lymphoma
7.14.1 Market Estimates & Forecast, 2020-2027
7.15 Others
Chapter 8. Global Antibody Drug Conjugate Market, by Product
8.1 Introduction
8.2 Adcertis
8.2.1 Market Estimates & Forecast, 2020-2027
8.3 Kadcyla
8.3.1 Market Estimates & Forecast, 2020-2027
8.4 Others
Chapter 9. Global Antibody Drug Conjugate Market, by Technology
9.1 Introduction
9.2 ImmunoGen technology
9.2.1 Market Estimates & Forecast, 2020-2027
9.3 Seattle Genetics technology
9.3.1 Market Estimates & Forecast, 2020-2027
9.4 Immunomedics technology
9.4.1 Market Estimates & Forecast, 2020-2027
9.4 Others
Chapter 10. Global Antibody Drug Conjugate Market, by End-User
10.1 Introduction
10.2 Hospitals
10.2.1 Market Estimates & Forecast, 2020-2027
10.3 Specialized Cancer Centers
10.3.1 Market Estimates & Forecast, 2020-2027
10.4 Academic Research Institutes
10.4.1 Market Estimates & Forecast, 2020-2027
10.5 Biopharmaceutical Companies
10.5.1 Market Estimates & Forecast, 2020-2027
10.6 Others
Chapter. 11 Global Antibody Drug Conjugate Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.1 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 Italy
11.3.1.4 Spain
11.3.1.5 U.K.
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 Republic of Korea
11.4.6 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 United Arab Emirates
11.5.2 Saudi Arabia
11.5.3 Rest of the Middle East & Africa
Chapter 12 Company Landscape
12.1 Introduction
12.2 Market Share Analysis
12.3 Key Development & Strategies
12.3.1 Key Developments
Chapter 13 Company Profiles
13.1 Seattle Genetics
13.1.1 Company Overview
13.1.2 Product Overview
13.1.3 Financials
13.1.4 SWOT Analysis
13.2 ImmunoGen, Inc.
13.2.1 Company Overview
13.2.2 Product Overview
13.2.3 Financial Overview
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.3 Roche Holding AG
13.3.1 Company Overview
13.3.2 Product Overview
13.3.3 Financial Overview
13.3.4 Key Development
13.3.5 SWOT Analysis
13.4 Genentech
13.4.1 Company Overview
13.4.2 Product/Business Segment Overview
13.4.3 Financial Overview
13.4.4 Key Development
13.4.5 SWOT Analysis
13.5 Concortis Biotherapeutics
13.5.1 Company Overview
13.5.2 Product Overview
13.5.3 Financial overview
13.5.4 Key Developments
13.6 AGENSYS, INC.
13.6.1 Company Overview
13.6.2 Product Overview
13.6.3 Financial Overview
13.6.4 Key Developments
13.7 Antikor
13.7.1 Overview
13.7.2 Product Overview
13.7.3 Financials
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.8 Immunomedics
13.8.1 Company Overview
13.8.2 Product/Business Segment Overview
13.8.3 Financial Overview
13.8.4 Key Development
13.8.5 SWOT Analysis
13.9 Pfizer Inc.
13.9.1 Company Overview
13.9.2 Product Overview
13.9.3 Financial overview
13.9.4 Key Developments
13.10 Others
Chapter 14 MRFR Conclusion
14.1 Key Findings
14.1.1 From CEO’s View Point
14.1.2 Unmet Needs of the Market
14.2 Key Companies to Watch
14.3 Prediction of the Pharmaceutical Industry
Chapter 15 Appendix
LIST OF TABLES
Table 1 Antibody Drug Conjugate Industry Synopsis, 2020-2027
Table 2 Antibody Drug Conjugate Market Estimates & Forecast, 2020-2027, (USD Million)
Table 3 Antibody Drug Conjugate Market, by Region, 2020-2027, (USD Million)
Table 4 Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 5 Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 6 Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 7 Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 8 Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 9 North America Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 10 North America Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 11 North America Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 12 North America Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 13 North America Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 14 U.S. Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 15 U.S. Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 16 U.S. Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 17 U.S. Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 18 U.S. Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 19 Canada Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 20 Canada Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 21 Canada Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 22 Canada Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 23 Canada Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 24 South America Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 25 South America Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 26 South America Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 27 South America Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 28 South America Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 29 Europe Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 30 Europe Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 31 Europe Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 32 Europe Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 33 Europe Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 34 Western Europe Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 35 Western Europe Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 36 Western Europe Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 37 Western Europe Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 38 Western Europe Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 39 Eastern Europe Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 40 Eastern Europe Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 41 Eastern Europe Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 42 Eastern Europe Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 43 Eastern Europe Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 44 Asia Pacific Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 45 Asia Pacific Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 46 Asia Pacific Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 47 Asia Pacific Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 48 Asia Pacific Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
Table 49 The Middle East & Africa Antibody Drug Conjugate Market, by Type, 2020-2027, (USD Million)
Table 50 The Middle East & Africa Antibody Drug Conjugate Market, by Application, 2020-2027, (USD Million)
Table 51 The Middle East & Africa Antibody Drug Conjugate Market, by Product, 2020-2027, (USD Million)
Table 52 The Middle East & Africa Antibody Drug Conjugate Market, by Technology, 2020-2027, (USD Million)
Table 53 The Middle East & Africa Antibody Drug Conjugate Market, by End-User, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Antibody Drug Conjugate Market
Figure 3 Segmentation Market Dynamics for Antibody Drug Conjugate Market
Figure 4 Global Antibody Drug Conjugate Market Share, by Type, 2020
Figure 5 Global Antibody Drug Conjugate Market Share, by Application, 2020
Figure 6 Global Antibody Drug Conjugate Market Share, by Product, 2020
Figure 8 Global Antibody Drug Conjugate Market Share, by Technology, 2020
Figure 9 Global Antibody Drug Conjugate Market Share, by End-User, 2020
Figure 10 Global Antibody Drug Conjugate Market Share, by Region, 2020
Figure 11 North America Antibody Drug Conjugate Market Share, by Country, 2020
Figure 12 Europe Antibody Drug Conjugate Market Share, by Country, 2020
Figure 13 Asia Pacific Antibody Drug Conjugate Market Share, by Country, 2020
Figure 14 The Middle East & Africa Antibody Drug Conjugate Market Share, by Country, 2020
Figure 15 Global Antibody Drug Conjugate Market: Company Share Analysis, 2020 (%)
Figure 16 Seattle Genetics: Key Financials
Figure 17 Seattle Genetics: Segmental Revenue
Figure 18 Seattle Genetics: Geographical Revenue
Figure 19 ImmunoGen, Inc.: Key Financials
Figure 20 ImmunoGen, Inc.: Segmental Revenue
Figure 21 ImmunoGen, Inc.: Geographical Revenue
Figure 22 Roche Holding AG: Key Financials
Figure 23 Roche Holding AG: Segmental Revenue
Figure 24 Roche Holding AG: Geographical Revenue
Figure 25 Genentech: Key Financials
Figure 26 Genentech: Segmental Revenue
Figure 27 Genentech: Geographical Revenue
Figure 28 Concortis Biotherapeutics: Key Financials
Figure 29 Concortis Biotherapeutics: Segmental Revenue
Figure 30 Concortis Biotherapeutics: Geographical Revenue
Figure 32 AGENSYS, INC.: Key Financials
Figure 33 AGENSYS, INC.: Segmental Revenue
Figure 34 AGENSYS, INC.: Geographical Revenue
Figure 35 Antikor: Key Financials
Figure 36 Antikor: Segmental Revenue
Figure 37 Antikor: Geographical Revenue
Figure 38 Immunomedics: Key Financials
Figure 39 Immunomedics: Segmental Revenue
Figure 40 Immunomedics: Geographical Revenue
Figure 41 Pfizer Inc.: Key Financials
Figure 42 Pfizer Inc.: Segmental Revenue
Figure 43 Pfizer Inc.: Geographical Revenue
Antibody Drug Conjugate Market
Antibody drug conjugate is expected to grow at a CAGR of approximately 23.5% during the forecast period 2022-2030
$23.65 billion
Market Size
23.5%
CAGR
North America
Dominating Region
2022-2030
Forecast Period
Segmentation
Key Players
- ADC Therapeutics
- Takeda Pharmaceutical Company Ltd.
- GlaxoSmithKline Plc
- Hoffmann-La Roche Ltd.
- Daiichi Sankyo Company Ltd.
- Pfizer Inc.
- Seagen Inc.
- Gilead Sciences Inc.
- Astellas Pharma
Drivers
- Advancement in the medical technology
- Obese population
- Growing ageing population
Antibody Drug Conjugate Market Overview
The antibody drug conjugate market size is expected to grow by 23.5% by 2030. The antibody drug conjugate is a crucial biopharmaceutical therapy for cancer treatment. It is an effective treatment that can eliminate cancer cells. Also, it only harms the cancer cells without harming the healthy cells in the body. There are plenty of benefits of the antibody-drug conjugate.
Due to its exceptional benefits, it is a treatment gaining high popularity in many regions. Patient recovery from cancer is faster with the antibody-drug conjugate. There are two major types of antibody-drug conjugate. The monoclonal and linker are two popular antibody drugs in the market. The prevalence of cancer is the factor that raises the demand for antibody-drug conjugate.
An unhealthy lifestyle and poor eating habits lead to more cancer cells in the body. The antibody-drug conjugate can identify and destroy cancer cells. The efficiency and effective mechanism are better than other cancer treatments. Due to its benefits, awareness about the treatment is increasing on a large scale. Biotechnology companies have tremendous demand for antibody-drug conjugate. In the forecast period, the market value will reach a high rate due to these factors. Also, the antibody drug conjugate market overview show massive expansion rate.
Covid analysis
The outbreak of covid 19 is bringing terrible effects on global markets. The slowdown in other medical treatments affects profitability. The health industry is more focused to treat the covid cases. Most of the hospitals and clinics were flooded with covid patients during the last year. Cancer research and treatments is delayed in the last few years. It is causing plenty of challenges to the antibody drug conjugate market.
There is a slowdown in the production of these drugs during a pandemic. Also, the number of cancer patients visiting hospitals has significantly reduced during this period. The research and programs related to cancer antibodies developments came to a halt during this period. However, the operations of the market are gradually resuming. The research and investment for the antibody conjugate market are rising in the upcoming years. Also, large scale research and production are expected to take place in the forecast period.
Market dynamics
- Crucial market drivers
Technological advancements are the crucial driver for this market. In recent years, the technological advancements in the healthcare sector are remarkable. It is a necessary development in the health sector to manage chronic diseases. As per the WHO reports, the ageing population will increase by 16% in the upcoming years. The number of individuals above 65 years of age is more prone to health complications. The cancer cases in aged people are higher than in the younger population.
Due to the increasing type and cases of cancer, the need for technological advancements is high. Innovation in medical technology leads to better treatment. With the use of better technologies, it is possible to provide the best treatment with the antibody-drug conjugate. Further, the demand for the market increases with the effected launch of technologies in the medical sector.
Moreover, the preclinical sector is increasing the research of antibodies for cancer. The investments for this sector are high in the upcoming years. It will result in advanced drug launches for most cancers. With the high rate of technological advancements, all these profitable events will take place in the antibody drug conjugate market. The increased antibody drug conjugate services will lead to a high revenue rate.
- Market growth opportunities
An increase in research and development will lead to antibody drug conjugate market growth opportunities. The research and development investments for the health sector are tremendous for the forecast period. It increases the therapy reset of antibody drugs. There are high chances for new drug discoveries in the market. The monoclonal antibodies segment is combined with chemical payloads. This combination leads to an effective immunotherapy arsenal for cancer. These positive developments will attract new end users to the market.
Due to high research, the collaboration of institutes and biopharmaceutical firms will grow in the upcoming years. The launch of new drugs through this collaboration is another actor leading to growth opportunities. Further, the key players are planning to increase their product range. The antibody drug conjugate market will witness innovations and new product launches in the forecast period. These growth opportunities will increase the overall profitability rate.
- The market restraints
The stringent governmental rule is the major restraint in this market. The use of antibody-drug conjugate requires plenty of compliance. The compliance and governmental standards delay the adoption of antibody drugs. The delayed reimbursement for this treatment is another restraint in the market.
The health insurance policies in many countries do not cover the pre-treatment for cancer. The antibody-drug conjugate is a preclinical treatment. The reimbursement for it is less. The lack of reimbursements and stringent government policies are the restraining factors of the market. It is a restraint that can cause the decline of demand for the market.
- The market challenge
The medical sector is advancing at a rapid pace. These advancements are causing plenty of developments in the cancer drug market. These developments may lead to better alternatives for the drug conjugate. Also, it can affect the overall demand of the antibody drug conjugate market in the forecast period.
The introduction of better alternatives can hamper the growth of the market. Further, the high cost of the treatment is another challenge in the market. The high cost of the procedure reduces the adoption rate of the market. Also, the demand can diminish due to the high cost and better alternatives.
- Cumulative growth analysis
The growth trend of the market is surging during the forecast period. The prevalence of chronic illnesses is raising the demand for the market. Further, the technological advancements in the medical industry are the crucial driver of this market. Technological advancement benefits the antibody drug conjugate market. The technologies enable better treatments and utilization.
The increasing investments in the health sector are providing more growth opportunities for the market. Innovation and progression will lead to market expansion. Increasing collaboration of the market with other institutions will bring positive impacts. However, stringent government rules are a restraining factor. Further, the high cost of the procedure is a major drawback for the market.
- Value chain analysis
North America will dominate with maximum antibody drug conjugate market share. The presence of key players is the crucial reason for high market growth. The awareness about the antibody drug conjugate market is high in this region. It leads to plenty of demand and development possibilities for the market.
The prevalence of cancer is creating an immense need in North America. Further, the rising R&D investments in this region will have a positive impact. There are fewer regulatory restrictions in this region for antibody-drug conjugates. Due to all these factors, North America will record the highest profitability rate.
Segment overview
By drug type
- Kadcyla
- Adcetris
By mechanism
- HER 2 antibodies
- CD30 antibodies
By application
- Breast cancer
- Lymphoma
By product
- Linker
- Monoclonal antibodies
By technology
- Immunogenic technology
- Immunomedics technology
By geography
- Asia pacific
- Europe
- North America
Competitive landscape
The competition in the antibody drug conjugate market is rising in the forecast period. The entry of new players will lead to more competition. Also, Expansions, product launches and innovation are a crucial part of the competitive landscape. Research and development will happen at a massive scale during the forecast period.
Regional analysis
The antibody drug conjugate market is diversified into Asia Pacific, Europe and North America. North America holds more than 50% of shares during the forecast period. The new types of cancer cases are leading to the tremendous demand for antibody-drug conjugate. The focus of the region is on the prediagnosis drug. With rising R&D expenditure the market will witness plenty of new developments. The presence top antibody drug conjugate companies is advantageous to the market.
The US market provides complete approval for the antibody-drug conjugate. The Asia Pacific is expected to be the fastest-growing antibody drug conjugate market in the forecast period. After America, Asia pacific is the next largest region with high cancer cases. There is a variety of new cancer cases in this region. Due to this, cancer treatment options are expanding rapidly. There is high demand and profitability for antibody-drug conjugate in Asia pacific.
The key players of the antibody drug conjugate market are
- ADC Therapeutics
- Takeda Pharmaceutical Company Ltd.
- GlaxoSmithKline Plc
- Hoffmann-La Roche Ltd.
- Daiichi Sankyo Company Ltd.
- Pfizer, Inc.
- Seagen, Inc.
- Gilead Sciences, Inc.
- Astellas Pharma
Recent developments
- The top institutes of oncology are choosing antibody-drug conjugate therapies. The adoption of the drug conjugates provides more awareness for the market.
- The Takeda pharmacy is partnering with top institutes. The Takeda and partnership firm will produce the therapies together.
Report overview
- Market overview highlights
- Analysis based upon COVID 19
- Explanation upon the Market Dynamics
- Value chain analysis
- Market segmentation overview
- 6. The regional analysis
- Competitive landscape analysis
- Recent Developments
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | Significant Value |
| CAGR | 23.5% |
| Base Year | 2019 |
| Forecast Period | 2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors and Trends |
| Segments Covered | Type, product, technology, application, and end-user |
| Geographies Covered | North America, Europe, Asia-Pacific and Rest of the World (RoW) |
| Key Vendors | Seattle Genetics (US), ImmunoGen, Inc. (US), Roche Holding AG (Switzerland), Genentech (US), Concortis Biotherapeutics (US), Agensys, Inc. (US), Antikor (UK), Immunomedics (US), Pfizer Inc. (US), Celldex Therapeutics (US), Millennium Pharmaceuticals (US), AbbVie Inc. (US), Bayer HealthCare (Germany), Astellas Pharma/Agensys (Japan), Progenics Pharmaceuticals (US), Mersana Therapeutics (US), Synthon (US), Heidelberg Pharma (Germany), Oxford BioTherapeutics (US) |
| Key Market Opportunities | Research activities |
| Key Market Drivers |
|
Frequently Asked Questions (FAQ) :
The antibody drug conjugate market is projected to grow at a CAGR of approximately 23.5% during the forecast period, 2020–2030.
Advancement in medical technology.
North America holds the largest share in the global antibody drug conjugate market followed by Europe and Asia Pacific, respectively.
ImmunoGen, Inc. (US), Seattle Genetics (US), Roche Holding AG (Switzerland), Concortis Biotherapeutics (US), Genentech (US), Agensys, Inc. (US), Immunomedics (US), Antikor (UK), Pfizer Inc. (US), Millennium Pharmaceuticals (US), Celldex Therapeutics (US), AbbVie Inc. (US), Astellas Pharma/Agensys (Japan), Bayer HealthCare (Germany), Progenics Pharmaceuticals (US), Synthon (US), Oxford BioTherapeutics (US), Mersana Therapeutics (US), and Heidelberg Pharma (Germany), are some of the major players operating in the global antibody drug conjugate market.
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global antibody drug conjugate market adopt to gain a larger competitive advantage.
